Evidence map›Paper›PMID 29476051›Full record

ArticleCell death & disease2018

CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3.

Xiaoxin Jin, Lifeng Cai, Changfa Wang, Xiaofeng Deng, Shengen Yi, Zhao Lei, Qiangsheng Xiao, Hongbo Xu, Hongwu Luo, Jichun Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Review
  3. LncRNA MEG3 RegulatesMicroorganisms · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Inhibition of induced-hepatic cancerFrontiers in oncology · 2022
    Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xiaoxin JinDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Lifeng CaiDepartment of General Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Changfa WangDepartment of General Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Xiaofeng DengDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Shengen YiDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Zhao LeiDepartment of General Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Qiangsheng XiaoDepartment of General Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Hongbo XuDepartment of General Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Hongwu LuoDepartment of General Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Jichun SunDepartment of General Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. 67247129@qq.com.ORCID 0000-0003-4222-0995
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma is one of the most common solid tumors in the digestive system. The prognosis of patients with hepatocellular carcinoma is still poor due to the acquisition of multi-drug resistance. TNF Related Apoptosis Inducing Ligand (TRAIL), an attractive anticancer agent, exerts its effect of selectively inducing apoptosis in tumor cells through death receptors and the formation of the downstream death-inducing signaling complex, which activates apical caspases 3/8 and leads to apoptosis. However, hepatocellular carcinoma cells are resistant to TRAIL. Non-coding RNAs, including long non-coding RNAs (lncRNAs) and miRNAs have been regarded as major regulators of normal development and diseases, including cancers. Moreover, lncRNAs and miRNAs have been reported to be associated with multi-drug resistance. In the present study, we investigated the mechanism by which TRAIL resistance of hepatocellular carcinoma is affected from the view of non-coding RNA regulation. We selected and validated candidate miRNAs, miR-24 and miR-221, that regulated caspase 3/8 expression through direct targeting, and thereby affecting TRAIL-induced tumor cell apoptosis TRAIL resistance of hepatocellular carcinoma. In addition, we revealed that CASC2, a well-established tumor suppressive long non-coding RNA, could serve as a "Sponge" of miR-24 and miR-221, thus modulating TRAIL-induced tumor cell apoptosis TRAIL resistance of hepatocellular carcinoma. Taken together, we demonstrated a CASC2/miR-24/miR-221 axis, which can affect the TRAIL resistance of hepatocellular carcinoma through regulating caspase 3/8; through acting as a "Sponge" of miR-24 and miR-221, CASC2 may contribute to improving hepatocellular carcinoma TRAIL resistance, and finally promoting the treatment efficiency of TRAIL-based therapies.

Indexed as

Drug Resistance, NeoplasmBase SequenceCarcinoma, HepatocellularCaspase 3Caspase 8Hep G2 CellsHumansLiver NeoplasmsMicroRNAsTNF-Related Apoptosis-Inducing LigandTumor Suppressor ProteinsCaspase 3Caspase 8long non-coding RNA CASC2, humanMicroRNAsMIR221, humanMIRN24 microRNA, humanTNF-Related Apoptosis-Inducing LigandTumor Suppressor Proteins

Identifiers

PMID29476051
PMCPMC5833678
OpenAlexW2793428705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.